

1 October 2009

**Lifeline Scientific, Inc.**  
**(“Lifeline” or the “Company”)**

**Total Voting Rights**

For the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 16,781,300.

The Company's issued share capital consists of 16,781,300 common shares, with one voting right per share and includes 74,061 common shares which have been issued by the Company since 11 August 2009 pursuant to the block listing.

The total number of voting rights in the Company is therefore 16,781,300.

The above figure of 16,781,300 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

As at today's date 8,521,294 common shares remain subject to Regulation S restrictions and are held in certificated form only. These common shares subject to Regulation S restrictions are traded under ISIN number USU529641008.

The remaining 8,260,006 common shares have had the Regulation S restrictions lifted and are held in uncertificated form trading under ISIN number US53223V1017.

On 30 September 2009 the Company purchased 1 common share from a private shareholder for cancellation at a price of \$1.

**Enquiries:**

**Lifeline Scientific, Inc.**

**+1 847 824 2420**

David Kravitz, CEO

**Seymour Pierce**

**+44 (0)20 7107 8000**

Mark Percy / Huaizheng Peng / Sarah Jacobs

**Financial Dynamics**

**+44 (0)20 7831 3113**

Ben Brewerton